ArticleCancer cell international2020
A four-DNA methylation signature as a novel prognostic biomarker for survival of patients with gastric cancer.
Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- An integrative multi-omics study to identify candidate DNA methylation biomarkers associated with gastric cancer prognosis.Archives of toxicology · 2025Article
- CNDP1 Overexpression by Promoter Hypomethylation Predicts Poor Prognosis and Immunotherapy Response in Mucosal Melanoma.Cancer science · 2025Article
- The Role of Epigenetic Mechanisms in the Treatment of GI Cancers.Current cancer drug targets · 2025Review
- Establishment of a 7-gene expression panel to improve the prognosis classification of gastric cancer patients.Frontiers in genetics · 2023Article
- Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.Frontiers in immunology · 2022Article
- Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer.Frontiers in oncology · 2022Article
- Role of the TSPO-NOX4 axis in angiogenesis in glioblastoma.Frontiers in pharmacology · 2022Article
- Article
- Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.Scientific reports · 2021Article
- Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.Frontiers in molecular neuroscience · 2021Article
- A Novel Six-Gene-Based Prognostic Model Predicts Survival and Clinical Risk Score for Gastric Cancer.Frontiers in genetics · 2021Article
- Recognition of DNA Methylation Molecular Features for Diagnosis and Prognosis in Gastric Cancer.Frontiers in genetics · 2021Article
- Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities.International journal of molecular sciences · 2020Review
- The Development of Three-DNA Methylation Signature as a Novel Prognostic Biomarker in Patients with Colorectal Cancer.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is the fifth most frequently diagnosed cancer and the third leading cause of cancer-related mortality. Lack of prognostic indicators for patient survival hinders GC treatment and survival. METHODS AND
resultsMethylation profile data of patients with GC obtained from The Cancer Genome Atlas (TCGA) database were analyzed to identify methylation sites as biomarkers for GC prognosis. The cohort was divided into training and validation sets. Univariate Cox, LASSO regression,and multivariate Cox analyses revealed a close correlation of a four-DNA methylation signature as a risk score model with the overall survival of patients with GC. The survival between high-risk and low-risk score patients with GC was significantly different. Analyses of receiver operating characteristics revealed a high prognostic accuracy of the four-DNA methylation signature in patients with GC. The subgroup analysis indicated that the accuracy included that for anatomical region, histologic grade, TNM stage, pathological stage, and sex. The GC prognosis based on the four-DNA methylation signature was more precise than that based on known biomarkers.
conclusionsThe four-DNA methylation signature could serve as a novel independent prognostic factor that could be an important tool to predict the prognostic outcome of GC patients. This potential must be verified in a large-scale population cohort study and through basic research studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.